ANIK
Income statement / Annual
Last year (2023), Anika Therapeutics, Inc.'s total revenue was $166.66 M,
an increase of 6.67% from the previous year.
In 2023, Anika Therapeutics, Inc.'s net income was -$82.67 M.
See Anika Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$166.66 M
|
$156.24 M
|
$147.79 M
|
$130.46 M
|
$114.61 M
|
$105.56 M
|
$113.42 M
|
$103.38 M
|
$93.00 M
|
$105.59 M
|
| Cost of Revenue |
$63.57 M |
$62.66 M |
$64.85 M |
$61.43 M |
$28.75 M |
$31.28 M |
$27.36 M |
$24.03 M |
$21.05 M |
$20.93 M |
| Gross Profit |
$103.09 M |
$93.58 M |
$82.94 M |
$69.03 M |
$85.86 M |
$74.28 M |
$86.06 M |
$79.35 M |
$71.95 M |
$84.66 M |
| Gross Profit Ratio |
0.62 |
0.6 |
0.56 |
0.53 |
0.75 |
0.7 |
0.76 |
0.77 |
0.77 |
0.8 |
| Research and Development
Expenses |
$32.69 M
|
$28.18 M
|
$27.33 M
|
$23.43 M
|
$16.67 M
|
$18.19 M
|
$18.79 M
|
$10.73 M
|
$8.99 M
|
$8.14 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$34.34 M
|
$21.54 M
|
$18.01 M
|
$14.83 M
|
$15.07 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$95.85 M
|
$84.79 M
|
$74.10 M
|
$60.06 M
|
$34.95 M
|
$34.34 M
|
$21.54 M
|
$18.01 M
|
$14.83 M
|
$15.07 M
|
| Other Expenses |
$75.94 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$191.48 M |
$112.98 M |
$101.42 M |
$83.49 M |
$51.62 M |
$52.53 M |
$40.33 M |
$28.75 M |
$23.81 M |
$23.22 M |
| Cost And Expenses |
$254.30 M |
$175.64 M |
$166.27 M |
$144.93 M |
$80.36 M |
$83.81 M |
$67.69 M |
$52.77 M |
$44.87 M |
$44.15 M |
| Interest Income |
$0.00 |
$654,000.00 |
$188,000.00 |
$498,000.00 |
$1.87 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$654,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$14.22 M
|
$16.35 M
|
$15.99 M
|
$15.00 M
|
$7.17 M
|
$5.91 M
|
$4.29 M
|
$3.73 M
|
$3.78 M
|
$4.71 M
|
| EBITDA |
$2.52 M
|
-$4.91 M
|
$2.62 M
|
-$12.83 M
|
$34.25 M
|
$27.66 M
|
$50.02 M
|
$54.34 M
|
$51.91 M
|
$61.45 M
|
| EBITDA Ratio |
0.02 |
-0.12 |
-0.27 |
-0 |
0.3 |
0.21 |
0.4 |
0.49 |
0.52 |
0.58 |
| Operating Income Ratio
|
-0.53
|
-0.12
|
-0.13
|
-0.11
|
0.3
|
0.21
|
0.4
|
0.49
|
0.52
|
0.58
|
| Total Other
Income/Expenses Net |
$2.31 M
|
$654,000.00
|
-$188,000.00
|
-$302,000.00
|
$1.87 M
|
$1.46 M
|
$473,000.00
|
$263,000.00
|
$120,000.00
|
$58,137.00
|
| Income Before Tax |
-$85.33 M |
-$18.75 M |
$2.43 M |
-$28.62 M |
$36.12 M |
$23.21 M |
$46.20 M |
$50.87 M |
$48.25 M |
$61.51 M |
| Income Before Tax Ratio
|
-0.51
|
-0.12
|
0.02
|
-0.22
|
0.32
|
0.22
|
0.41
|
0.49
|
0.52
|
0.58
|
| Income Tax Expense |
-$2.66 M |
-$3.89 M |
-$1.71 M |
-$4.64 M |
$8.93 M |
$4.49 M |
$14.39 M |
$18.32 M |
$17.50 M |
$23.19 M |
| Net Income |
-$82.67 M |
-$14.86 M |
$4.13 M |
-$23.98 M |
$27.19 M |
$18.72 M |
$31.82 M |
$32.55 M |
$30.76 M |
$38.32 M |
| Net Income Ratio |
-0.5 |
-0.1 |
0.03 |
-0.18 |
0.24 |
0.18 |
0.28 |
0.31 |
0.33 |
0.36 |
| EPS |
-5.64 |
-1.02 |
0.29 |
-1.69 |
1.93 |
1.3 |
2.18 |
2.22 |
2.06 |
2.61 |
| EPS Diluted |
-5.64 |
-1.02 |
0.28 |
-1.69 |
1.89 |
1.27 |
2.11 |
2.15 |
2.01 |
2.51 |
| Weighted Average Shares
Out |
$14.66 M
|
$14.56 M
|
$14.40 M
|
$14.22 M
|
$14.12 M
|
$14.44 M
|
$14.58 M
|
$14.68 M
|
$14.93 M
|
$14.68 M
|
| Weighted Average Shares
Out Diluted |
$14.66 M
|
$14.56 M
|
$14.63 M
|
$14.22 M
|
$14.37 M
|
$14.69 M
|
$15.07 M
|
$15.12 M
|
$15.32 M
|
$15.27 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
